Truist Financial Upgrades WAVE Life Sciences (NASDAQ:WVE) to Strong-Buy

WAVE Life Sciences (NASDAQ:WVE) was upgraded by stock analysts at Truist Financial to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

WVE has been the subject of several other reports. Leerink Partners reissued an “outperform” rating on shares of WAVE Life Sciences in a research report on Monday, December 8th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of WAVE Life Sciences in a research note on Monday, March 2nd. UBS Group set a $32.00 price objective on shares of WAVE Life Sciences in a report on Tuesday, December 16th. Royal Bank Of Canada raised shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $9.00 to $27.00 in a research report on Monday, December 8th. Finally, Mizuho raised their target price on WAVE Life Sciences from $22.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.31.

WAVE Life Sciences Price Performance

Shares of NASDAQ WVE opened at $6.20 on Wednesday. WAVE Life Sciences has a one year low of $5.02 and a one year high of $21.73. The business’s 50-day moving average price is $13.08 and its two-hundred day moving average price is $11.20. The company has a market capitalization of $1.17 billion, a P/E ratio of -5.08 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The firm had revenue of $17.25 million for the quarter, compared to analysts’ expectations of $15.68 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%. On average, equities analysts anticipate that WAVE Life Sciences will post -1.14 EPS for the current year.

Insider Activity

In related news, CFO Kyle Moran sold 3,588 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $48,258.60. Following the transaction, the chief financial officer directly owned 134,385 shares in the company, valued at approximately $1,807,478.25. This trade represents a 2.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Chandra Vargeese sold 3,228 shares of WAVE Life Sciences stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $43,416.60. Following the completion of the transaction, the insider owned 408,246 shares in the company, valued at $5,490,908.70. This trade represents a 0.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 61,748 shares of company stock valued at $907,809 in the last quarter. 23.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On WAVE Life Sciences

A number of institutional investors have recently made changes to their positions in the business. GSK plc bought a new stake in WAVE Life Sciences during the 4th quarter valued at approximately $310,177,000. Adage Capital Partners GP L.L.C. grew its holdings in WAVE Life Sciences by 20.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after buying an additional 2,500,000 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in WAVE Life Sciences by 83.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock worth $125,927,000 after buying an additional 3,362,880 shares during the period. Darwin Global Management Ltd. acquired a new position in shares of WAVE Life Sciences during the fourth quarter worth approximately $125,168,000. Finally, Federated Hermes Inc. lifted its holdings in shares of WAVE Life Sciences by 26.5% during the fourth quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company’s stock worth $80,657,000 after buying an additional 993,827 shares during the last quarter. 89.73% of the stock is currently owned by institutional investors.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: The company reported interim Phase 1 INLIGHT data showing placebo‑adjusted improvements at six months — visceral fat down ~14%, total fat down ~5%, lean mass +2%, waist circumference down ~3.3% — and continued safety/tolerability. These signals support the drug’s mechanistic promise (body‑composition benefit). Read More.
• Positive Sentiment: Some analysts and outlets highlight the trial’s body‑composition gains and safety profile as a reason to view the selloff as a buying opportunity; Mizuho recently raised its price target and Truist upgraded the stock. Read More.
• Neutral Sentiment: Coverage emphasizes the distinction between clinically meaningful visceral‑fat reductions and the modest absolute weight loss observed — important context for assessing commercial potential but ambiguous for near‑term valuation. Read More.
• Negative Sentiment: Market reaction: the higher‑dose results were widely described as disappointing because they did not produce clear additional weight loss, prompting a massive selloff and extreme intraday volume as investors exited on efficacy concerns and lower near‑term commercial prospects. Read More.
• Negative Sentiment: Multiple news outlets framed the update as “underwhelming” and noted the tiny (~1%) change in body weight over six months despite visceral‑fat gains — headlines and analyst downgrades amplified selling pressure. Read More.
• Negative Sentiment: Legal risk: a plaintiff firm is publicly soliciting shareholders about potential securities claims tied to the company’s disclosures, adding regulatory and litigation uncertainty that can prolong downward pressure. Read More.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.